Skip to main content

  • Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis

    • Posted: 10/31/2023
    • Author:

      Eva C.I. Woelders, Jasper J.P. Luijkx, Laura Rodwell, Patty J.C. Winkler, Aukelien C. Dimitriu-Leen, Pieter C. Smits, Niels van Royen, Arnoud W.J. van't Hof, Peter Damman and Robert Jan M. van Geuns

    • 2023CRM

    Abstract

    Background

    P2Y12 inhibitor monotherapy is a promising novel strategy to reduce bleeding complications compared to dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI). In order to personalise treatment with DAPT based on patients' bleeding risk, we compared outcomes after PCI between P2Y12 inhibitor monotherapy and DAPT according to bleeding risk.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details